First Tracks Biotherapeutics is trading 4.81% down at $45.96, with no confirmed company-specific catalyst and broad market weakness the likeliest context.
- On November 5, 2026, major U.S. indexes were sharply lower, though supplied sector data showed biotech rising.
- The recent Q3 update reported a narrower $31.4 million loss, $343 million pro forma cash, and planned ANB033 milestones; available coverage does not establish that these results caused the decline.